Service d'Allergologie
Rouen, 76031, France
NCT Number: NCT07034313
Allergy testing is necessary to confirm a diagnosis of allergy, whether food, respiratory, drug, or hymenoptera venom.
Although the vast majority of these tests are well tolerated, performing them carries a very low risk of inducing an allergic reaction in the patient, warranting continuous medical monitoring regardless of the allergy being investigated.
A severe reaction can be observed, largely during oral or intravenous reintroduction tests, in up to 15% of series for food allergies, and even less for drug allergies.
The perceived risk can vary between patients, and this subjective perception can be influenced by several factors, including personal experience, medical history, or access to information regarding allergy testing. Anxiety related to allergy testing can influence patient experience, but also test results.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Rouen, 76031, France
The assessment of this anxiety and understanding of the factors that influence it remain understudied, particularly in patients undergoing allergy testing. This study seeks to measure this anxiety and the factors that may influence it, in order to tailor personalized care for each patient.
This study will be conducted through the administration of a standardized questionnaire designed to measure the anxiety of patients undergoing allergy testing, as well as several parameters that may influence this anxiety, such as the prevalence of depression and anxiety disorders, and personality traits influenced by stress, using specific and validated scores.
This questionnaire will be administered to patients attending Rouen University Hospital for skin allergy testing and oral or intravenous provocation testing.
This descriptive study will focus on analyzing patients' perceptions and experiences without directly interfering with the medical procedures performed. Patients' perceptions and experiences will be collected using statements that will be rated on a Likert scale by the patients
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 day
The primary endpoint will be the visual analogue anxiety scale with a score ranging from 0 (total absence of anxiety) to 10 (maximum anxiety), before allergy testing is performed.
Time frame: 1 day
Anxiety-depressive disorders will be assessed using the HAD (Hospital Anxiety and Depression scale) questionnaire, administered to patients included in the study.
Time frame: 1 day
Anxiety-depressive disorders will be assessed using the PSS (Perceived Stress Scale) questionnaire, administered to patients included in the study.
Time frame: 1 day
Information on the care pathway will be collected using closed (multiple choice) questions (general information).
Time frame: 1 day
The results of the allergy tests will be studied by consulting the clinical file, and will be analyzed for their association with anxiety levels.
University Hospital, Rouen
Other
Rouen Study on Anxiety During Allergy Tests
Acronym: ERATA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06333925
Anxiety Disorder, Anxiety Disorders
Durham, North Carolina, United States
View Trial DetailsNCT07045818
Anxiety Disorder, Anxiety Disorders
Shenyang, Liaoning, China
View Trial DetailsNCT01117753
Anxiety Disorder, Anxiety Disorders
Charleston, South Carolina, United States
View Trial DetailsNCT04182061
Anxiety Disorder, Anxiety Disorders
Madrid, Spain
View Trial Details